Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine |
| |
| Authors: | A. L. Barry M. A. Pfaller P. C. Fuchs F. C. Tenover L. B. Reller S. D. Allen D. J. Hardy E. H. Gerlach |
| |
| Affiliation: | (1) The Clinical Microbiology Institute, P.O. Box 947, 97062 Tualatin, Oregon, USA;(2) Oregon Health Sciences University, 97201 Portland, Oregon, USA;(3) St. Vincent Hospital and Medical Center, 97225 Portland, Oregon, USA;(4) Centers for Disease Control, 30333 Atlanta, Georgia, USA;(5) Duke University Medical Center, 27710 Durham, North Carolina, USA;(6) University of Indiana Medical Center, 46223 Indianapolis, Indiana, USA;(7) University of Rochester Medical Center, 14642 Rochester, New York, USA;(8) St. Francis Regional Medical Center, 67214 Wichita, Kansas, USA |
| |
| Abstract: | Studies with fosfomycin tromethamine disks containing 200 µg of fosfomycin and 50 µg of glucose-6-phosphate confirmed the following zone diameter criteria for the NCCLS method:  12 mm for resistant (MIC 256 µg/ml), 13–15 mm for intermediate (MIC 128 µg/ml) and 16 mm for susceptible (MIC64 µg/ml). Additional studies defined acceptable MIC and zone diameter ranges for the following quality control strains:Escherichia coli ATCC 25922, MIC 0.5 to 4.0 µg/ml, zone diameter 23 to 29 mm;Staphylococcus aureus ATCC 25923, zone diameter 26 to 32 mm;Pseudomonas aeruginosa ATCC 27813, MIC 2.0 to 8.0 µg/ml; andEnterococcus faecalis, ATCC 29212, MIC 16 to 64 µg/ml. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
